Clinical Trials Arena on MSN
Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD
Alar’s ketamine-based drug mitigates certain adverse events, which could eliminate the need for post-dose monitoring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results